Эвагенретцел

Rec. INN (наименование, зарегистрированное ВОЗ)

Cell-based gene therapy consisting of a genetically modified cell line, derived from human donor-derived retinal pigment epithelial (RPE) cells. The cell line was transfected sequentially with two plasmids (p834 and p910) expressing the same fusion protein composed of: signal peptide and domain 2 of VEGFR1 (vascular endothelial growth factor receptor 1, FLT1) (VEGFR1(D2)); domain 3 of VEGFR2 (vascular endothelial growth factor receptor 2, KDR) (VEGFR2(D3)); and hinge domain, CH2 region and CH3 region of human immunoglobulin G1 (IgG1) under the control of a promoter containing a mouse cytomegalovirus (mCMV) enhancer, the human elongation factor 1-alpha (EF1-alpha) core promoter and a synthetic intron (I 126).

Поделиться этой страницей